Drug intelligence / Profile preview

Dantonic (Tasly Group)

Development stage: Unknown
Lead developer: Tasly Pharmaceuticals, Inc.
Modality: Small Molecules
Administration: Oral

Overview

Dantonic (T89) is a botanical drug developed by Tasly Pharmaceuticals for the treatment and prevention of chronic stable angina pectoris. It is a standardized herbal formulation containing extracts of Radix Salviae Miltiorrhizae (Danshen) and Radix Notoginseng (Sanqi), along with borneol as an absorption enhancer. The drug's mechanism involves improving coronary blood circulation, enhancing myocardial energy metabolism, and reducing blood viscosity. It has been approved in over 20 countries outside the United States and has undergone extensive Phase III clinical testing for the US market.

Brand names: Dantonic
Other names: Compound Danshen Dripping PillsCDDP

Beyond the preview

Go deeper on Dantonic (Tasly Group).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Dantonic (Tasly Group).

Explore the full profile